All In Biotech

Drug Trial Radar · NCT07142252

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

May 14, 2026

Primary completion

May 25, 2028

Study completion May 25, 2028

Sponsor

Sponsor type
NIH
First posted
Aug 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study is a 2-arm, multi-center, double-masked (masking of the participant, care provider and investigator), placebo-controlled, 2:1 randomized trial design in new onset T1D participants (within 100 days of diagnosis). Participants will be administered rezpegaldesleukin/placebo once every 14 days over 26 weeks with an additional 6-month follow-up period.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • RezpegaldesleukinDrug

    Rezpegaldesleukin will be dosed at 12 μg/kg for subcutaneous injection. Rezpegaldesleukin will be provided as a 1.5 mg/mL sterile solution in a vial for injection preparation. Study agent injections will be administered in the abdomen, back of the upper arm or the upper thigh of the participant.

  • PlaceboDrug

    Sterile saline for injection. Placebo will be administered in the same volume and as the active comparator to maintain treatment masking.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The area under the stimulated C-peptide curve (AUC) Y_MAUC.Time frame: 12 Months

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California · Recruiting

  • Barbara Davis Center for Diabetes

    Aurora, Colorado · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • USF Diabetes Center

    Tampa, Florida · Recruiting

  • Indiana University-Riley Hospital for Children

    Indianapolis, Indiana · Recruiting

  • Joslin Diabetes Center

    Boston, Massachusetts · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Columbia University

    New York, New York · Recruiting

  • University of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • Vanderbilt University

    Nashville, Tennessee · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • Benaroya Research Institute

    Seattle, Washington · Recruiting

  • University of British Columbia

    Vancouver, British Columbia, Canada · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.